Promentis Pharmaceuticals Inc. announced it received a $299,000 grant from the Michael J. Fox Foundation to conduct further research into compounds that show promise for treating Parkinson's disease.
Promentis is Marquette’s first-ever pharmaceutical start-up company, which is currently exploring novel drug compounds for the treatment of schizophrenia and other central nervous system disorders. The company was founded by Drs. David Baker and John Mantsch, both professors in the Department of Biomedical Sciences in the College of Health Sciences. Baker currently serves as a director for Promentis and chairs its Scientific Advisory Board.